Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis

BACKGROUND AND AIMS: Golimumab has been approved recently to treat refractory moderate-to-severe ulcerative colitis [UC]. To date it is not clear why a considerable fraction of patients do not respond, or lose initial response, to golimumab therapy. Our aim was to investigate whether a low golimumab...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Crohns Colitis
Egile Nagusiak: Detrez, Iris, Dreesen, Erwin, Van Stappen, Thomas, de Vries, Annick, Brouwers, Els, Van Assche, Gert, Vermeire, Séverine, Ferrante, Marc, Gils, Ann
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2016
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4957447/
https://ncbi.nlm.nih.gov/pubmed/26738756
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjv241
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak